Login / Signup

Inclusion of harm outcomes in core outcome sets requires careful consideration.

Joel TayCatherine RobinsonJane BlazebyYoon LokeAoife LoweryBilal AlkhaffafJamie J Kirkham
Published in: Journal of clinical epidemiology (2024)
Harm outcomes are already included in many COS either as individual or pooled harms. It is evident that there are some challenges with regards to both the methodology and necessity to include harms within a COS (pooled or individual. COS developers should carefully consider the need to include important harms outcomes in relation to the scope of the COS that they are developing.
Keyphrases
  • clinical trial
  • metabolic syndrome
  • weight loss
  • insulin resistance
  • glycemic control
  • phase iii
  • study protocol
  • double blind